DDDR-38. A LENTIVIRAL CRISPR SCREEN FOR EPIGENETIC MODULATORS OF CAR T CELL-TARGETED ANTIGENS IN GLIOBLASTOMA CELL LINES

Abstract Glioblastoma is the most common malignant brain tumor. Unfortunately, outcomes for this cancer are poor. Even with standard of care treatment, median survival time only 15 months and disease almost universally lethal. Therefore, more effective therapies urgently needed to treat condition. One promising treatment chimeric antigen receptor (CAR) T cell therapy. CAR cells white blood that engineered kill expressing certain antigens; however, potential has yet be fully realized further work required it effective. strategy augmenting therapy would increase expression targeted antigens on cells. This could done using small molecule inhibitors epigenetic pathways regulate these antigens. goal study was screen genes currently being in clinical trials glioblastoma. Using a CRISPR/Cas9 lentiviral vector library, we knocked out various encoding proteins human glioblastoma lines. Flow cytometry used sort highest levels target surface expression. Genomic DNA isolated from interest. The sequenced identify genetic manipulations responsible increased Future studies will use identified modulators augment mice.